Orphazyme A/S
Company announcement
No. 07/2019
Company Registration No. 32266355
Copenhagen, Denmark, March 5, 2019 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by closely associated persons to persons discharging managerial responsibilities in Orphazyme:
1 Details of the Reporting Person / Closely Associated Person
a) Name
GFD Investments LLC
2 Reason for the notification
a) Position/status
Closely associated person to Georges Gemayel, Chairman of the Board of Directors
b) Initial notification/Amendment
Initial notification
3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Purchase of shares
c) Price(s) and volume(s)
| Price (s) | Volume(s) |
| DKK 48.80 | 525 |
| DKK 48.80 | 19 |
| DKK 48.80 | 643 |
| DKK 48.80 | 180 |
| DKK 49.00 | 40 |
| DKK 49.00 | 874 |
| DKK 48.05 | 289 |
| DKK 47.00 | 1,989 |
| DKK 50.00 | 520 |
| DKK 50.00 | 1,000 |
| DKK 50.00 | 225 |
| DKK 50.00 | 70 |
| DKK 49.00 | 427 |
| DKK 49.50 | 126 |
| DKK 49.90 | 700 |
| DKK 50.00 | 363 |
| DKK 49.00 | 895 |
| DKK 49.90 | 212 |
| DKK 49.90 | 501 |
| DKK 49.85 | 2 |
d) Aggregated information
- Aggregated volume
- Price
Aggregated volume: 9,600
Price: DKK 48.8946
e) Date of the transaction
2019-03-04 – between 10:00 and 13:00 UTC-time
f) Place of the transaction
Nasdaq Copenhagen A/S - XCSE
For additional information, please contact
Orphazyme A/S
Anders Vadsholt, CFO +45 28 98 90 55
About Orphazyme A/S
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.
Forward-looking statement
This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Attachment
